{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":7,"youtube":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06790693\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"INAVO123","nct_id":"NCT06790693","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=inavo123-nct06790693. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"INAVO123","arms":[{"description":"Participants will receive inavolisib, letrozole and CDK4/6i.","label":"Inavolisib + Letrozole + CDK4/6i","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo, letrozole and CDK4/6i.","label":"Placebo + Letrozole + CDK4/6i","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-02-01","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":450,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Inavolisib","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"CDK4/6i","type":"DRUG"},{"name":"Letrozole","type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 7 years)"}],"references":[],"start_date":{"date":"2025-04-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06790693"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/inavo123-nct06790693"}